Controversy Toward American Oriental Bioengineering (AOB)

September 22, 2009 · Filed Under General, flu 

American Oriental Bioengineering Inc. (NYSE: AOB) is being highlighted by a service which the company probably wished did not cover it.  If you recall a websire called Asensio.com, and active site that highlights short selling opportunities or red flags in companies, Shenzen, China-based American Oriental Bioengineering is the new target of such activity.

If you look at the “Recent Reports” section at Asensio.com, there are two highted articles both dated as of today.  One article is “AOB Chairman’s Questionable Second Passport and Potential Undisclosed Conflicts of Interest” and another article is “AOB’s Disclosures Concerning Director Cosimo Patti Appear Incomplete.”

You will need to go through these individually before making your own call.  The notion that one short seller or one independent service highlights a company is something that should be checked and measured by each investor.

Shares were down early in the pre-market session, but the stock was actually back to positive right after the open.  At 9:39 AM Est we have shares up 0.3% at $5.39.  The 52-week trading range is $3.29 to $7.66 and the average volume is over 1.4 million shares.

American Oriental Bioengineering, Inc. is a Chinese pharmaceutical company “dedicated to improving health through the development, manufacture and commercialization of a broad range” of prescription and over the counter products.  The market cap of this one is $421 million.

JON C. OGG
September 22, 2009

Tags:

Comments

Comments are closed.

    Subscribe to BioHealth Investor BioHealth Investor RSS Feed